Serum Malondialdehyde as a Biomarker of Oxidative Stress in Patients with Primary Ocular Carcinoma: Impact on Response to Chemotherapy.
biomarker
chemotherapy
malignancy
malondialdehyde
oxidative stress
Journal
Clinical ophthalmology (Auckland, N.Z.)
ISSN: 1177-5467
Titre abrégé: Clin Ophthalmol
Pays: New Zealand
ID NLM: 101321512
Informations de publication
Date de publication:
2021
2021
Historique:
received:
24
10
2020
accepted:
31
12
2020
entrez:
5
3
2021
pubmed:
6
3
2021
medline:
6
3
2021
Statut:
epublish
Résumé
To study the level of serum malondialdehyde (MDA), a biomarker of oxidative stress before and after chemotherapy in various ocular malignancies and to correlate its significance with clinicopathological parameters. Thirty two histopathologically confirmed cases of primary ocular malignancies were included in this longitudinal cohort study. Detailed clinicopathological assessment was done. Analysis of serum MDA level in the patient before and after chemotherapy was measured and its prognostic significance was analyzed. Maximum cases were of eyelid malignancy (n=18, 56.2%) followed by retinoblastoma (18.8%) and OSSN (6, 18.8%). About 43.75% patients were in the advanced-stage. The tumor was histopathologically well-differentiated in 20 (62.5%) cases. Most common malignancy was sebaceous gland carcinoma of the eyelid (n=10,31.25%). Serum MDA level in patients were significantly higher than controls [5.5712±0.32779 vs 2.5531±0.08056 nmol/mL, p<0.001]. Level was significantly reduced after chemotherapy (4.5146±0.23209 nmol/mL). Serum MDA was maximum in cases of rhabdomyosarcoma (5.9450±0.23335 nmol/mL) and retinoblastoma (5.7433±0.14334 nmol/mL). It was minimum in basal cell carcinoma (5.3775±0.17746 nmol/mL). Pre chemotherapy serum MDA level was significantly higher in patients having larger tumor (>20mm, p< 0.001) and having lymph node metastasis than those without lymph node metastasis [5.8350±0.17113 vs 5.4833± 0.32193 nmol/mL, p<0.006]. No significant difference was observed in post chemotherapy serum MDA level as for as size of tumor (p=0.947) and histopathological differentiation (p=0.109) was concerned. The serum MDA level is a potential biomarker in primary ocular carcinoma to assess oxidative stress and its impact on response to chemotherapy.
Identifiants
pubmed: 33664564
doi: 10.2147/OPTH.S287747
pii: 287747
pmc: PMC7924123
doi:
Types de publication
Journal Article
Langues
eng
Pagination
871-879Informations de copyright
© 2021 Maurya et al.
Déclaration de conflit d'intérêts
The authors declare no potential conflicts of interest.
Références
J Exp Clin Cancer Res. 2008 Nov 04;27:62
pubmed: 18983683
Ophthalmology. 2001 Nov;108(11):2088-98; quiz 2099-100, 2121
pubmed: 11713084
Ophthalmology. 1991 Dec;98(12):1867-73
pubmed: 1775323
J Clin Oncol. 2008 Jun 10;26(17):2839-45
pubmed: 18539962
Free Radic Res. 2011 Apr;45(4):477-82
pubmed: 21250785
Respir Med. 2006 Jan;100(1):157-66
pubmed: 15890507
Cell Biochem Funct. 2007 Jul-Aug;25(4):377-82
pubmed: 16447143
Nutr Cancer. 2000;37(1):1-18
pubmed: 10965514
Cancer Res. 2006 Feb 15;66(4):1883-90; discussion 1895-6
pubmed: 16488983
Cancer Epidemiol Biomarkers Prev. 2002 Mar;11(3):267-73
pubmed: 11895876
Altern Med Rev. 1999 Oct;4(5):304-29
pubmed: 10559547
Free Radic Biol Med. 1991;10(3-4):185-90
pubmed: 1864523
Cancer. 1989 Jul 15;64(2):422-5
pubmed: 2544250
Int Ophthalmol Clin. 2009 Winter;49(1):111-21
pubmed: 19125070
Arch Physiol Biochem. 2001 Oct;109(4):331-6
pubmed: 11935368
J Clin Pharm Ther. 2008 Apr;33(2):179-85
pubmed: 18315784
Ann Oncol. 2011 May;22(5):1109-1112
pubmed: 20924074
Jpn J Ophthalmol. 1995;39(1):65-70
pubmed: 7643486
Biochem J. 1988 Feb 15;250(1):247-52
pubmed: 3128276
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Jpn J Clin Oncol. 2002 May;32(5):162-6
pubmed: 12110642
Ophthalmologica. 2005 Mar-Apr;219(2):57-71
pubmed: 15802929
Jpn J Ophthalmol. 2005 Sep-Oct;49(5):349-54
pubmed: 16187033
Dermatol Online J. 2008 Aug 15;14(8):8
pubmed: 19061568
Integr Cancer Ther. 2004 Dec;3(4):294-300
pubmed: 15523100
Surv Ophthalmol. 2005 Mar-Apr;50(2):103-22
pubmed: 15749305
Ophthalmology. 1999 Apr;106(4):746-50
pubmed: 10201597
Anal Biochem. 1979 Jun;95(2):351-8
pubmed: 36810
Ophthalmic Plast Reconstr Surg. 1988;4(2):73-80
pubmed: 3154725
Ageing Res Rev. 2013 Jan;12(1):376-90
pubmed: 23123177
Am J Ophthalmol. 1988 Dec 15;106(6):723-9
pubmed: 3195651
Blood. 2000 Jul 1;96(1):307-13
pubmed: 10891466
J Cancer Res Ther. 2010 Oct-Dec;6(4):487-91
pubmed: 21358086
Chem Phys Lipids. 1987 Nov-Dec;45(2-4):337-51
pubmed: 3319232
Respirology. 2010 Feb;15(2):349-56
pubmed: 20199646
Eur J Cancer Prev. 1997 Feb;6(1):3-10
pubmed: 9161806
Surv Ophthalmol. 1993 Sep-Oct;38(2):169-92
pubmed: 8235999